Uniqure NV (NASDAQ:QURE) Director Paula Soteropoulos Sells 9,082 Shares

Share on StockTwits

Uniqure NV (NASDAQ:QURE) Director Paula Soteropoulos sold 9,082 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $64.26, for a total transaction of $583,609.32. Following the completion of the transaction, the director now directly owns 18,234 shares in the company, valued at $1,171,716.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Paula Soteropoulos also recently made the following trade(s):

  • On Monday, December 9th, Paula Soteropoulos sold 2,500 shares of Uniqure stock. The stock was sold at an average price of $67.50, for a total transaction of $168,750.00.

QURE stock traded up $2.03 during trading on Tuesday, reaching $65.03. 38,932 shares of the stock were exchanged, compared to its average volume of 514,920. The company has a current ratio of 14.33, a quick ratio of 14.33 and a debt-to-equity ratio of 0.19. The business has a 50 day moving average price of $53.34 and a 200-day moving average price of $57.78. Uniqure NV has a 1 year low of $24.07 and a 1 year high of $82.49. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of -27.80 and a beta of 0.79.

Uniqure (NASDAQ:QURE) last issued its earnings results on Monday, October 28th. The biotechnology company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.23. Uniqure had a negative net margin of 1,670.86% and a negative return on equity of 51.12%. The company had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.24 million. On average, research analysts anticipate that Uniqure NV will post -2.98 EPS for the current year.

A number of hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Uniqure by 21.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,975 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 346 shares during the period. Parametric Portfolio Associates LLC raised its stake in Uniqure by 8.4% during the second quarter. Parametric Portfolio Associates LLC now owns 4,835 shares of the biotechnology company’s stock worth $378,000 after purchasing an additional 376 shares during the period. US Bancorp DE raised its stake in Uniqure by 275.5% during the second quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 427 shares during the period. Griffin Asset Management Inc. acquired a new stake in shares of Uniqure during the second quarter valued at about $39,000. Finally, Royal Bank of Canada increased its position in shares of Uniqure by 9.7% during the second quarter. Royal Bank of Canada now owns 6,075 shares of the biotechnology company’s stock valued at $474,000 after acquiring an additional 536 shares during the last quarter. 73.13% of the stock is currently owned by institutional investors.

Several equities analysts have recently weighed in on the stock. Mizuho reissued a “buy” rating and issued a $90.00 price target (up from $67.00) on shares of Uniqure in a research note on Tuesday. Stifel Nicolaus assumed coverage on shares of Uniqure in a research note on Friday, October 11th. They issued a “buy” rating and a $79.00 price target on the stock. Cowen assumed coverage on shares of Uniqure in a research note on Tuesday, December 3rd. They issued an “outperform” rating on the stock. BidaskClub raised shares of Uniqure from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Finally, Goldman Sachs Group assumed coverage on shares of Uniqure in a research note on Tuesday, December 3rd. They issued a “buy” rating and a $98.00 price target on the stock. Two research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Uniqure presently has a consensus rating of “Buy” and an average target price of $79.20.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Featured Story: Growth Stocks, What They Are, What They Are Not

Insider Buying and Selling by Quarter for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CWM Advisors LLC Decreases Stake in National-Oilwell Varco, Inc.
CWM Advisors LLC Decreases Stake in National-Oilwell Varco, Inc.
CWM Advisors LLC Sells 287 Shares of Watts Water Technologies Inc
CWM Advisors LLC Sells 287 Shares of Watts Water Technologies Inc
James Investment Research Inc. Purchases 1,095 Shares of iShares Russell 1000 Value ETF
James Investment Research Inc. Purchases 1,095 Shares of iShares Russell 1000 Value ETF
James Investment Research Inc. Purchases 46,666 Shares of iShares MSCI South Korea ETF
James Investment Research Inc. Purchases 46,666 Shares of iShares MSCI South Korea ETF
PNM Resources Inc  Shares Sold by James Investment Research Inc.
PNM Resources Inc Shares Sold by James Investment Research Inc.
James Investment Research Inc. Acquires 30,776 Shares of Radian Group Inc
James Investment Research Inc. Acquires 30,776 Shares of Radian Group Inc


© 2006-2020 Ticker Report